New drug targets Hard-to-Treat cancers in early trial
NCT ID NCT06840119
First seen Feb 01, 2026 · Last updated May 14, 2026 · Updated 21 times
Summary
This early-phase study tests a new drug, IMC-R117C, in people with advanced colorectal, esophageal, stomach, or ovarian cancers that have a specific protein (PIWIL1) and a certain immune type (HLA-A*02:01). The goal is to see if the drug is safe and can shrink tumors. About 600 adults will take part, and the drug may be given alone or with other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Antoni van Leeuwenhoek
RECRUITINGAmsterdam, Netherlands
-
Centro Integral Oncologico Clara Campal
RECRUITINGMadrid, Spain
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
RECRUITINGRoma, Italy
-
Hospital HM Nou Delfos
RECRUITINGBarcelona, Spain
-
Hospital Universitario Fundacion Jimenez Diaz
RECRUITINGMadrid, Spain
-
Institut Jules Bordet
RECRUITINGAnderlecht, 1070, Belgium
-
Peter MacCallum Cancer Centre
RECRUITINGMelbourne, Australia
-
St Vincent's Hospital
ACTIVE_NOT_RECRUITINGDarlinghurst, Sydney, NSW 2010, Australia
-
UZ Leuven
RECRUITINGLeuven, 3000, Belgium
-
Universitaetsklinikum Heidelberg
RECRUITINGHeidelberg, Germany
-
Universitair Ziekenhuis Gent
RECRUITINGGhent, Belgium
-
VHIO, Vall d'Hebron University Hospital
RECRUITINGBarcelona, Spain
-
nstituto Clinico Humanitas
RECRUITINGRozzano, 20089, Italy
Conditions
Explore the condition pages connected to this study.